Revenue grew 11.1% in 2025, driven by Rx (+33%) and digital services (+110%), with strong margin gains and a robust liquidity position. EBITDA breakeven is targeted for 2026, supported by platform expansion, cost control, and a new Google partnership.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.